fashion -WSS

fashion

author：knowledge 2025-09-07 17:23:52 - browse：97237

TRENTON, N.J. — Pharma industry giants including Bristol Myers Squibb, Johnson & Johnson, Novartis, and Novo Nordisk deployed a half-dozen lawyers to a courtroom here Thursday in a bid to dismantle Medicare’s new drug price negotiation program, just hours before President Biden is set to glorify it in his State of the Union.

A federal judge in New Jersey heard an unusual quadruple oral argument in which attorneys for all four drugmakers combined forces to challenge different facets of the Inflation Reduction Act, which in 2022 empowered Medicare to negotiate the prices of a small number of drugs each year beginning in 2026.

Over four hours, the debate spanned most of the substantive issues that pharmaceutical companies and their allies have raised across the country, both in constitutional challenges to the law and in challenges to how Medicare officials have interpreted the law so far. That means the court’s decision in these cases could produce a first substantive test for several of the arguments that haven’t been addressed by courts in other states, where companies like Boehringer Ingelheim, AstraZeneca, and Merck are also suing, separately, over the same law.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： {$word} {$title}
Next article： NIH director takes cautious approach to Biden drug pricing priority

WSS

Why Eli Lilly’s earnings didn’t quite live up to the hype

Congress considering partial increase for doctor pay in Medicare

Doctors on social media are being harassed and cyberbullied

STAT Boddities: What happens to the brain when we get scared?

Why doctors need education on FDA device approval process

Congress must protect the remaining independent doctors

knowledge

fashion

Wikipedia

Heart attack and stroke risk calculators need revising

FDA clears AI tool for detecting skin cancer

Trump demands the U.S. pay no more for drugs than other countries … again

Elizabeth Holmes banned from government health programs

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Francis Collins on trust in science and how Covid communications failed

Hepatitis C has a cure — but many Americans still lack access to it

Medicare Advantage today, explained in one chart

Hepatitis C has a cure — but many Americans still lack access to it

Research misconduct: Proposed new rules face resistance

focus

Abbott's new heart device gets FDA advisory panel nod

Long Covid research funding gets a major boost from NIH

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Humana cuts profit projections as Medicare Advantage costs soar

Why don't Americans have at

Ebola vaccine can save some who are already sick, per new study

Wikipedia

Wikipedia

focus

focus